Testing blood markers to guide chemo for metastatic nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study looks at special blood markers (CTCs) to see how sensitive your cancer is to chemotherapy and to better predict how well treatment may work. If you have metastatic nasopharyngeal cancer and can’t have local treatment, this may help match you to more effective chemo plans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nasopharyngeal cancer that has spread to distant parts after 3 months of radiation and local treatment isn’t possible
- You have at least one measurable spot of cancer that doctors can track on scans
- You’re age 18 to 70, and your health status is good (ECOG 0 to 1)
- Your expected survival is at least 3 months, and you can give informed consent
- Your blood counts and organ tests are high enough to safely receive treatment (white blood cells, neutrophils, hemoglobin, platelets, and liver/kidney function)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses advanced testing (multi-omics) to predict if combining chemoradiation with immunotherapy works better for nasopharyngeal cancer that has returned or spread. It aims to find the right treatment for each person.
This trial tests a new combination of immunotherapy (JS001) and chemotherapy (PFLL) versus a standard regimen (GP) for people with nasopharyngeal cancer that has spread. The goal is to see if the new combination works better at controlling the disease.
This trial tests a combination of chemotherapy (three drugs: docetaxel, cisplatin, and fluorouracil) plus an immunotherapy drug (a PD-1 inhibitor, which helps your immune system fight cancer) given before the standard radiation treatment for nasopharyngeal cancer. The goal is to see if this upfront treatment can improve outcomes in patients whose cancer has not spread to distant parts of the body.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests whether adding a new drug (BL-B01D1) to an immunotherapy maintenance treatment can help keep nasopharyngeal cancer from growing after initial chemotherapy. It aims to improve how long patients live without the cancer progressing.
This trial tests whether giving radiation therapy to the main tumor right after chemo-immunotherapy is better than waiting until the cancer comes back, in people with newly diagnosed metastatic nasopharyngeal cancer. It aims to see which approach helps you live longer and have fewer side effects.
Hear when a new Circulating Tumor Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.